These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 7771918)

  • 1. Duration of neuroleptic treatment and prevalence of tardive dyskinesia in late life.
    Sweet RA; Mulsant BH; Gupta B; Rifai AH; Pasternak RE; McEachran A; Zubenko GS
    Arch Gen Psychiatry; 1995 Jun; 52(6):478-86. PubMed ID: 7771918
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The prevalence of tardive dyskinesia in neuroleptic-treated diabetics. A controlled study.
    Ganzini L; Heintz RT; Hoffman WF; Casey DE
    Arch Gen Psychiatry; 1991 Mar; 48(3):259-63. PubMed ID: 1671743
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tardive dyskinesia in the aged. Duration of treatment relationships.
    Toenniessen LM; Casey DE; McFarland BH
    Arch Gen Psychiatry; 1985 Mar; 42(3):278-84. PubMed ID: 2858189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tardive dyskinesia in elderly psychiatric patients: a 5-year study.
    Yassa R; Nastase C; Dupont D; Thibeau M
    Am J Psychiatry; 1992 Sep; 149(9):1206-11. PubMed ID: 1354413
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intermittent neuroleptic treatment and risk for tardive dyskinesia: Curaçao Extrapyramidal Syndromes Study III.
    van Harten PN; Hoek HW; Matroos GE; Koeter M; Kahn RS
    Am J Psychiatry; 1998 Apr; 155(4):565-7. PubMed ID: 9546009
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of severe and mild tardive dyskinesia: implications for etiology.
    Gardos G; Cole JO; Schniebolk S; Salomon M
    J Clin Psychiatry; 1987 Sep; 48(9):359-62. PubMed ID: 2887550
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Neuroleptic use, parkinsonian symptoms, tardive dyskinesia, and associated factors in child and adolescent psychiatric patients.
    Richardson MA; Haugland G; Craig TJ
    Am J Psychiatry; 1991 Oct; 148(10):1322-8. PubMed ID: 1680296
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Not all that moves is tardive dyskinesia.
    Khot V; Wyatt RJ
    Am J Psychiatry; 1991 May; 148(5):661-6. PubMed ID: 1673323
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of tardive dyskinesia in older patients. A prospective longitudinal study of 266 outpatients.
    Jeste DV; Caligiuri MP; Paulsen JS; Heaton RK; Lacro JP; Harris MJ; Bailey A; Fell RL; McAdams LA
    Arch Gen Psychiatry; 1995 Sep; 52(9):756-65. PubMed ID: 7654127
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prospective study of tardive dyskinesia in the elderly: rates and risk factors.
    Woerner MG; Alvir JM; Saltz BL; Lieberman JA; Kane JM
    Am J Psychiatry; 1998 Nov; 155(11):1521-8. PubMed ID: 9812112
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Changing epidemiology of tardive dyskinesia: an overview.
    Jeste DV; Wyatt RJ
    Am J Psychiatry; 1981 Mar; 138(3):297-309. PubMed ID: 6110344
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study.
    Morgenstern H; Glazer WM
    Arch Gen Psychiatry; 1993 Sep; 50(9):723-33. PubMed ID: 8102845
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ten-year outcome of tardive dyskinesia.
    Gardos G; Casey DE; Cole JO; Perenyi A; Kocsis E; Arato M; Samson JA; Conley C
    Am J Psychiatry; 1994 Jun; 151(6):836-41. PubMed ID: 7910437
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dyskinesia and neuroleptic exposure in elderly psychiatric inpatients.
    Sweet RA; Mulsant BH; Rifai AH; Zubenko GS
    J Geriatr Psychiatry Neurol; 1992; 5(3):156-61. PubMed ID: 1353963
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tardive dystonia. Prevalence, risk factors, and comparison with tardive dyskinesia in a population of 200 acute psychiatric inpatients.
    Raja M
    Eur Arch Psychiatry Clin Neurosci; 1995; 245(3):145-51. PubMed ID: 7669821
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The prevalence of tardive dyskinesia.
    Woerner MG; Kane JM; Lieberman JA; Alvir J; Bergmann KJ; Borenstein M; Schooler NR; Mukherjee S; Rotrosen J; Rubinstein M
    J Clin Psychopharmacol; 1991 Feb; 11(1):34-42. PubMed ID: 1674949
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients.
    Jeste DV; Lacro JP; Palmer B; Rockwell E; Harris MJ; Caligiuri MP
    Am J Psychiatry; 1999 Feb; 156(2):309-11. PubMed ID: 9989570
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Neuroleptic-related dyskinesias in children and adolescents.
    Connor DF; Fletcher KE; Wood JS
    J Clin Psychiatry; 2001 Dec; 62(12):967-74. PubMed ID: 11780878
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of neuroleptic-induced dyskinesia and parkinsonism: the influence of measurement methods and definitions.
    Dean CE; Kuskowski MA; Caligiuri MP
    J Clin Psychopharmacol; 2006 Dec; 26(6):560-5. PubMed ID: 17110811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Incidence of tardive dyskinesia with atypical versus conventional antipsychotic medications: a prospective cohort study.
    Woods SW; Morgenstern H; Saksa JR; Walsh BC; Sullivan MC; Money R; Hawkins KA; Gueorguieva RV; Glazer WM
    J Clin Psychiatry; 2010 Apr; 71(4):463-74. PubMed ID: 20156410
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.